Shots:
- Janssen reported pooled analyses of long-term follow-up from multiple clinical trials evaluating the use of Imbruvica monothx. and in combination as a 1L treatment for patients with CLL with high-risk features
- Results from an integrated analysis of two clinical trials with ~79mos. of follow-up demonstrated PFS rates (63%-82%) @42mos.; median duration of treatment across high-risk subgroups (35.7-43.8 mos.)
- Additionally, data with a median follow-up of >4yrs. were presented from a pooled analysis of 89 patients with high-risk CLL bearing TP53 aberrations from 4 trials. Further, data from the RWE studies highlight the benefit of ibrutinib-based therapies in a 1L setting
Click here to read full press release/ article | Ref: Businesswire | Image: LBC
The post Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia first appeared on PharmaShots.
